Overview

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Anidulafungin
Caspofungin
Echinocandins